This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
May 3 (posted viaProZ.com): I finished the translation and editing of a systematic review about the role of melatonin in the treatment of neonatal encephalopathy...more »
English to French: Mélatonine dans le traitement de l'encéphalopathie néonatale General field: Medical Detailed field: Medical: Health Care
Source text - English Eligibility criteria
We included all randomised and quasi‐randomised controlled trials in newborns with NE comparing the use of melatonin and TH versus standard treatment (including TH), and also melatonin monotherapy versus standard treatment (with no TH). We excluded cross‐over randomised trials and non‐randomised cohort studies. We excluded studies that included preterm newborns born at less than 34 weeks gestational age (GA) or studies that included newborns with major congenital anomalies.
Outcomes
The critical outcome for both comparisons was the combined outcome of mortality or NDD at ≥ 18 months of age.
Our important outcomes included differences in mortality (up to one month), NDD (at ≥ 18 months), abnormalities on a brain MRI (at one month), multiorgan dysfunction (up to one month), and use of anti‐seizure medications (up to one month).
Synthesis methods
We synthesised results for each outcome using meta‐analysis by calculating odds ratios with 95% confidence intervals. Where this was not possible due to the nature of the data, we summarised the results narratively. We used GRADE to assess the certainty of evidence for prespecified outcomes. We examined the effects of melatonin treatment and TH versus standard care (with TH) and the effects of melatonin monotherapy versus standard care (without TH).
Included studies
We included four studies including 155 participants. Sample sizes ranged from 20 to 80 participants per study. The mean age of participants ranged from 36.8 to 39.5 weeks' GA at birth. The proportion of males in the studies ranged from 54% to 76%. The proportion of participants with severe NE ranged from 20% to 59%. Follow‐up periods ranged from time of discharge to 18 months of life.
Translation - French Source: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013754.pub2/full/fr
Critères d’éligibilité
Nous avons inclus tous les essais contrôlés randomisés et quasi randomisés chez des nouveau-nés atteints d’une encéphalopathie néonatale (EN), comparant l’utilisation de la mélatonine associée à l’hypothermie thérapeutique (HT) au traitement standard (incluant HT), ainsi que la monothérapie à base de mélatonine par rapport au traitement standard (sans HT). Les essais randomisés en cross-over et les études de cohorte non randomisées ont été exclus. Les études portant sur des nouveau-nés prématurés de moins de 34 semaines d’âge gestationnel ou présentant des anomalies congénitales majeures ont également été exclues.
Critères de jugement
Le critère de jugement principal pour les deux comparaisons était un critère composite associant décès ou troubles neurodéveloppementaux (TN) à l’âge de 18 mois ou plus. Les critères secondaires importants comprenaient la mortalité à un mois, les TN à 18 mois ou plus, les anomalies à l’IRM cérébrale à un mois, la dysfonction multiviscérale et l’utilisation de médicaments antiépileptiques au cours du premier mois de vie.
Méthodes de synthèse
Les résultats ont été synthétisés par méta-analyse en calculant des rapports de cotes avec des intervalles de confiance à 95 %. Lorsque la synthèse quantitative n’était pas possible, une analyse narrative a été réalisée. Le niveau de confiance des données probantes a été évalué selon l’approche GRADE.
Études incluses
Quatre essais contrôlés randomisés (155 participants) ont été inclus. Deux études ont évalué la mélatonine associée à l’HT par rapport aux soins standards (avec HT), et deux ont évalué la monothérapie par mélatonine par rapport aux soins standards (sans HT). Les participants étaient des nouveau-nés à terme ou proches du terme atteints d’EN, avec une proportion de formes sévères variant de 20 % à 59 %. Le suivi s’étendait jusqu’à 18 mois.
More
Less
Translation education
Graduate diploma - Chartered Institute of Linguists
Experience
Years of experience: 2. Registered at ProZ.com: Mar 2026. Became a member: May 2026.
CIOL-qualified translator with Master's degree in psychology
• Specialising in scientific/medical translation, working between French and English
• CertTrans qualification from the Chartered Institute of Linguists (CIOL), Master’s degree in Psychology, and Associate Member of the CIOL
Contact: www.linkedin.com/in/gwladys-j-5140b43b1
This user has reported completing projects in the following job categories, language pairs, and fields.
Project History Summary
Total projects
1
With client feedback
0
Corroborated
0
0 positive (0 entries)
positive
0
neutral
0
negative
0
Job type
Translation
1
Language pairs
English to French
1
Specialty fields
Medical: Health Care
1
Other fields
Keywords: French to English translation, English to French translation, French translation, medical translation, scientific translation, certified translator, CIOL, editing, proofreading, MTPE. See more.French to English translation, English to French translation, French translation, medical translation, scientific translation, certified translator, CIOL, editing, proofreading, MTPE, localization, scientific articles, research articles, psychology translation, neuroscience translation, CAT tools, technical translation, native speaker, experienced, specialized, specialized translator, qualified translator. See less.
Member since May '26
Portfolio 
positive
